Carboplatin plus Taxol is an Effective Third-line Regimen in Recurrent Undifferentiated Nasopharyngeal Carcinoma

Abstract

The combination has a good palliative role as third-line chemotherapy in recurrent undifferentiated nasopharyngeal cancer.

Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy Compared with Concurrent Chemoradiotherapy Alone for the Treatment of Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Controlled Study

“…New drugs have to be explored for inclusion in ac treatment regimens. Paclitaxel, docetaxel, gemcitabine, and capecitabine are new cytotoxic agents that have shown activity in treating both npc and non-nasopharyngeal head-and-neck cancers [20][21][22][23] . In a trial by He et al 22 , 54 patients with locoregionally advanced npc were treated with 2 cycles of cisplatin-gemcitabine as neoadjuvant chenotherapy, followed by 2 cycles of the same regimen administered as ac.…”

Nasopharyngeal Cancer

“…These include the anti-metabolites (e.g., gemcitabine (Foo et al 2002;Ngan et al 2002;, 5-fl uorouracil (Fandi et al 1997), capecitabine Li et al 2008), methotrexate (Molinari 1978) ), alkylating agents (e.g., cyclophosphamide (Molinari 1978), ifosfamide (Stein et al 1996), microtubule inhibitors (e.g., paclitaxel (Tan et al 1999;Yeo et al 1998;Au et al 1998;Airoldi et al 2002), docetaxel (Hui et al 2009Johnson et al 2004) ), anthracyclines (e.g., epirubicin (Azli et al 1995), doxorubicin (Molinari 1978), mitoxantrone (Dugan et al 1993) ), vinca alkal oids (vinorelbine ), irinotecan , bleomycin Molinari 1978), and mitomycin C (Hong et al 1999) (Table 11.1). These include the anti-metabolites (e.g., gemcitabine (Foo et al 2002;Ngan et al 2002;, 5-fl uorouracil (Fandi et al 1997), capecitabine Li et al 2008), methotrexate (Molinari 1978) ), alkylating agents (e.g., cyclophosphamide (Molinari 1978), ifosfamide (Stein et al 1996), microtubule inhibitors (e.g., paclitaxel (Tan et al 1999;Yeo et al 1998;Au et al 1998;Airoldi et al 2002), docetaxel (Hui et al 2009Johnson et al 2004) ), anthracyclines (e.g., epirubicin (Azli et al 1995), doxorubicin (Molinari 1978), mitoxantrone (Dugan et al 1993) ), vinca alkal oids (vinorelbine ), irinotecan , bleomycin Molinari 1978), and mitomycin C (Hong et al 1999) (Table 11.1).…”

Systemic treatment strategies and therapeutic monitoring for advanced nasopharyngeal carcinoma

“…As monotherapy, doses at 135-175 mg/m 2 given every 3 weeks are well tolerated, with a response rate of 22% [39], and when combined with carboplatin, response rates of 60-72% have been reported [49][50][51]. Attempts at dose-escalating paclitaxel only exacerbated toxicity, without improving response rate [50,52].…”

“…Carboplatinpacltaxel 25 9.5 [51] Foo 27 Gemcitabine 48 7.2 [54] Chua 17 Capecitabine 23.5 7.6 [59] Poon 28 Irinotecan 14 11.4 [62] Wang 39 Gemcitabinevinorelbine 36 11.9 [60] regulation of viral latency and restriction of viral gene expression in NPC [72]. CpG island methylation has also been implicated in the epigenetic inactivation of cellular (nonviral) tumor suppressor genes and, therefore, may contribute to NPC carcinogenesis [71].…”